Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $1.7 million.

  • Precision Biosciences' Cash from Financing Activities fell 5555.85% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year decrease of 5023.86%. This contributed to the annual value of $50.4 million for FY2024, which is 83651.38% up from last year.
  • Precision Biosciences' Cash from Financing Activities amounted to $1.7 million in Q3 2025, which was down 5555.85% from $5.3 million recorded in Q2 2025.
  • Precision Biosciences' 5-year Cash from Financing Activities high stood at $92.9 million for Q2 2022, and its period low was -$180000.0 during Q3 2022.
  • Over the past 5 years, Precision Biosciences' median Cash from Financing Activities value was $4.5 million (recorded in 2024), while the average stood at $13.3 million.
  • As far as peak fluctuations go, Precision Biosciences' Cash from Financing Activities surged by 1159267.52% in 2021, and later crashed by 10151.06% in 2022.
  • Quarter analysis of 5 years shows Precision Biosciences' Cash from Financing Activities stood at $8.4 million in 2021, then tumbled by 102.15% to -$180000.0 in 2022, then soared by 1671.11% to $2.8 million in 2023, then surged by 109.34% to $5.9 million in 2024, then crashed by 71.98% to $1.7 million in 2025.
  • Its Cash from Financing Activities was $1.7 million in Q3 2025, compared to $5.3 million in Q2 2025 and $10.7 million in Q1 2025.